clinical trial · NCT06732154
A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects
Fujian Shengdi Pharmaceutical Co., Ltd.·phase1·completed·n = 50
DyslipidemiaHRS-5632Placebo
brief summary
The study is being conducted to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of HRS-5632 Following a Single Subcutaneous Injection in Healthy Subjects
started
Dec 2, 2024
primary completion
Mar 2, 2026
completion
Mar 2, 2026
last updated
Apr 3, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol